©IDOSR PUBLICATIONS

ISSN: 2550-794X

International Digital Organization for Scientific Research IDOSRJSR9.3.813100
IDOSR JOURNAL OF SCIENTIFIC RESEARCH 9(3)8-13, 2024.
https://doi.org/10.59298/IDOSRJSR/2024/9.3.813.100

The Role of Inflammation and Immune Dysregulation in the Pathogenesis of BPH

Bizimana Rukundo T.

Faculty of Biological Sciences Kampala International University Uganda

ABSTRACT

Benign prostatic hyperplasia (BPH) is a prevalent non-cancerous enlargement of the prostate that affects a significant proportion of aging men, often resulting in bothersome lower urinary tract symptoms (LUTS). While traditionally linked to hormonal imbalances, particularly dihydrotestosterone (DHT), emerging evidence has increasingly highlighted the critical role of chronic inflammation and immune dysregulation in BPH pathogenesis. Inflammatory infiltrates comprising immune cells such as macrophages, lymphocytes, and neutrophils are frequently observed in the prostates of men with BPH. This inflammatory response promotes cellular proliferation, disrupts apoptosis, and induces fibrosis, leading to prostate enlargement. Factors such as infections, autoimmune reactions, and oxidative stress contribute to this chronic inflammatory environment, which is further exacerbated by systemic inflammation associated with aging and metabolic disturbances. This review explores the mechanisms by which chronic inflammation drives BPH progression, including cytokine-mediated cell proliferation and growth factor-induced fibrosis, as well as the imbalance between pro-apoptotic and anti-apoptotic signaling in prostate tissues. Furthermore, it delves into the potential of immune-targeted therapies as a novel approach to treating BPH, focusing on cytokine inhibitors, immune modulation, and anti-inflammatory agents. These therapies, which address the underlying inflammatory processes in BPH, offer promise in not only alleviating symptoms but also in slowing disease progression. By understanding the role of inflammation and immune dysregulation in BPH, novel therapeutic strategies may emerge, potentially revolutionizing the management of this common condition.

Keywords: Benign prostatic hyperplasia (BPH), Chronic inflammation, Immune dysregulation, Prostate enlargement, Immune-targeted therapies

INTRODUCTION

Benign prostatic hyperplasia (BPH) is one of the most prevalent urological conditions among aging men, significantly impacting their quality of life [1] It is a non-cancerous enlargement of the prostate gland, typically occurring in men over the age of 50. The condition is characterized by the proliferation of both stromal and epithelial cells within the prostate, leading to compression of the urethra and causing bothersome lower urinary tract symptoms (LUTS) such as urinary frequency, urgency, nocturia, and difficulty initiating urination [2,3]. Although BPH is not life-threatening, the chronic nature of its symptoms can significantly impair daily functioning, leading many men to seek medical intervention [4].

Traditionally, the etiology of BPH has been closely linked to hormonal imbalances, particularly involving androgens [5]. Dihydrotestosterone (DHT), a potent derivative of testosterone, has long been recognized as a major driver of prostatic growth. The aging process, coupled with increased activity of 5-alpha-reductase (the enzyme responsible for converting testosterone to DHT), was thought to contribute primarily to the development of BPH [6]. However, as our understanding of the condition has evolved, it has become increasingly clear that BPH is a multifactorial disease. Beyond hormonal influences, genetic predispositions, lifestyle factors, and

metabolic disorders have been implicated in its pathogenesis [7].

In recent years, a growing body of evidence has highlighted the crucial role that chronic inflammation and immune dysregulation play in the development and progression of BPH. Inflammatory infiltrates have been commonly observed in the prostates of men with BPH, with a variety of immune cells, including macrophages, lymphocytes, and neutrophils, found within prostatic tissues [8,9]. The presence of these cells suggests that the prostate is not merely undergoing a benign hyperplastic process, but is also responding to an ongoing inflammatory stimulus, which may act as a key driver of hyperplasia [10]. Chronic inflammation has been shown to stimulate cellular proliferation, impair apoptotic processes, and induce fibrotic changes within the prostate [11]. Immune cells within the inflamed prostate release a variety of cytokines, growth factors, and reactive oxygen species (ROS) that create a pro-inflammatory microenvironment, promoting tissue remodeling and hyperplasia [12]. This inflammatory response may be triggered by a range of stimuli, including infections, autoimmune reactions, oxidative stress, and metabolic disturbances. Importantly, systemic low-grade inflammation, often seen in aging and obesity, may exacerbate local inflammation within the prostate, further contributing to its enlargement [13]. The involvement of inflammation and immune dysregulation in BPH pathogenesis opens up exciting new avenues for therapeutic intervention. Traditional treatments for BPH, such as alpha-blockers and 5-alpha-reductase inhibitors, focus primarily on relieving urinary symptoms or reducing the size of the prostate [14]. However, they do not address the underlying inflammatory processes that contribute to the disease's progression. As a result, immune-targeted therapies, including anti-inflammatory agents and immune modulators, are emerging as potential novel treatment options for BPH [15]. Understanding how chronic inflammation and immune responses contribute to prostate enlargement could revolutionize the management of BPH, offering more targeted and effective treatments aimed at modifying the disease process itself, rather than merely controlling symptoms. This review delves into the critical role of inflammation and immune dysregulation in the pathogenesis of BPH. It examines how chronic inflammation contributes to prostate enlargement and explores the potential of immune-targeted therapies in treating BPH, offering hope for more effective, long-term management of this common condition.

Understanding BPH Pathogenesis

BPH is characterized by the proliferation of stromal and epithelial cells within the transition zone of the prostate, leading to the formation of large nodules that compress the urethra [16]. This compression results in lower urinary tract symptoms (LUTS), such as increased urinary frequency, nocturia, and difficulty initiating urination. Traditionally, BPH pathogenesis has been attributed to androgen signaling, specifically the role of dihydrotestosterone (DHT), an active metabolite of testosterone that stimulates prostatic cell growth [17]. However, it has become evident that inflammation and immune responses are critical in the progression and severity of BPH.

Inflammation and Immune Dysregulation in BPH

The Role of Inflammation in BPH

Chronic inflammation is frequently observed in the prostates of men with BPH, often associated with histological evidence of inflammatory infiltrates consisting of lymphocytes, macrophages, and neutrophils [18]. Inflammatory processes within the prostate are thought to result from a variety of stimuli, including:

1. **Infections:** Bacterial infections (e.g., Escherichia coli and Enterococcus species) can trigger chronic prostatitis, leading to sustained inflammatory responses.
2. **Autoimmune Reactions:** Some studies suggest that autoimmunity may play a role in BPH, where autoantigens trigger T-cell activation and subsequent chronic inflammation.
3. **Oxidative Stress:** Reactive oxygen species (ROS) generated by inflammatory cells can cause tissue damage, stimulating fibroblast activity and promoting hyperplasia [19-21]

Inflammation within the prostate can induce the release of cytokines and growth factors, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and transforming growth factor-beta (TGF-β) [22]. These signaling molecules stimulate fibroblast and smooth muscle cell proliferation, leading to prostatic enlargement. Additionally, inflammation may disrupt the balance of pro-apoptotic and anti-apoptotic factors, further promoting cellular hyperplasia.

Immune Dysregulation and BPH Progression

Beyond localized inflammation, BPH has been linked to systemic immune dysregulation. Immune cells

infiltrating the prostate may alter the local tissue environment, initiating and sustaining inflammation through an interplay between innate and adaptive immune responses. The infiltration of T cells, especially CD4+ and CD8+ T lymphocytes, is frequently noted in BPH tissues [23]. Th1, Th2, and Th17 cells play different roles in the immune landscape of BPH:

Th1 Cells: These cells secrete pro-inflammatory cytokines, including interferon-gamma (IFN-γ) and TNF-α, which exacerbate local inflammation.

Th17 Cells: Associated with autoimmune responses, Th17 cells promote the recruitment of neutrophils and macrophages, further enhancing inflammatory processes.

Regulatory T Cells (Tregs): Reduced numbers of Tregs in the prostate microenvironment have been associated with excessive inflammation, as Tregs typically act to suppress immune responses and maintain tolerance [24].

This immune dysregulation, coupled with chronic inflammation, leads to the remodeling of prostate tissue, which may facilitate hyperplasia. Moreover, systemic low-grade inflammation, often seen in aging men, can exacerbate local prostate inflammation, creating a vicious cycle that perpetuates BPH development [25].

Mechanisms Linking Chronic Inflammation to Prostate Enlargement

Cytokine-Mediated Cell Proliferation

Cytokines such as IL-6, IL-8, and TNF-α play pivotal roles in mediating inflammation-induced cell proliferation. IL-6, in particular, is a known driver of prostatic epithelial cell proliferation and has been found at elevated levels in patients with BPH. IL-6 can activate downstream signaling pathways, including the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, which promotes the transcription of genes involved in cell survival and proliferation [26].

Growth Factors and Fibrosis

Chronic inflammation also leads to the upregulation of growth factors such as TGF-β, which induces fibrosis within the prostate. Fibrosis contributes to the stiffening of prostate tissue and may compress the urethra, exacerbating LUTS. TGF-β has been shown to stimulate fibroblast proliferation and differentiation into myofibroblasts, a key cell type involved in fibrosis [27].

Disrupted Apoptosis and Tissue Homeostasis

In a healthy prostate, tissue homeostasis is maintained through a balance between cell proliferation and apoptosis. Chronic inflammation disrupts this balance, favoring hyperplasia. Pro-inflammatory cytokines can inhibit apoptotic pathways, leading to an accumulation of stromal and epithelial cells, a hallmark of BPH [28]

Potential for Immune-Targeted Therapies in BPH

Given the emerging evidence linking inflammation and immune dysregulation to BPH pathogenesis, immune-targeted therapies hold promise as a novel treatment strategy. Several potential therapeutic avenues are under investigation:

Cytokine Inhibitors

Targeting specific cytokines involved in the inflammatory cascade may reduce prostatic inflammation and slow disease progression. IL-6 inhibitors, for example, have been explored in various inflammatory conditions, and their application in BPH is being considered. TNF-α blockers, which are used in autoimmune diseases like rheumatoid arthritis, may also hold potential in reducing prostatic inflammation [29].

Immune Modulation

Restoring immune balance in the prostate microenvironment through the modulation of T cells is another potential therapeutic approach. Therapies aimed at increasing the number or function of Tregs could help suppress excessive inflammation and prevent hyperplasia. Additionally, strategies to inhibit Th17-mediated inflammation could provide therapeutic benefits [30].

Antioxidants and Anti-inflammatory Agents

Given the role of oxidative stress in promoting inflammation and fibrosis, the use of antioxidants and anti-inflammatory agents is an area of growing interest. Non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors have shown promise in reducing BPH-related symptoms by targeting inflammatory pathways. However, their long-term use carries potential side effects, necessitating the development of safer alternatives [31].

Phytotherapeutics

Certain plant-based compounds have been explored for their anti-inflammatory and immunomodulatory properties in BPH. For instance, saw palmetto extract, derived from Serenoa repens, is widely used for managing BPH symptoms. Its mechanism of action is thought to involve inhibition of 5-alpha-reductase, reduction of pro-inflammatory cytokine production, and suppression of immune cell infiltration in the prostate [32].

CONCLUSION

The role of inflammation and immune dysregulation in the pathogenesis of BPH is gaining increasing recognition, offering new insights into the mechanisms driving prostate enlargement. Chronic inflammation, fueled by immune cell infiltration and cytokine production, promotes cell proliferation, fibrosis, and disrupted apoptosis, contributing to the development of BPH. Immune-targeted therapies, including cytokine inhibitors, immune modulators, and anti-inflammatory agents, represent promising strategies for addressing the underlying inflammatory processes in BPH. Future research aimed at elucidating the complex interplay between inflammation, immune responses, and prostate tissue remodeling will be essential in developing effective therapies that not only manage symptoms but also target the root causes of BPH progression.

REFERENCES

1. Park S, Ryu JM, Lee M. Quality of Life in Older Adults with Benign Prostatic Hyperplasia. Healthcare (Basel). 2020 Jun 4;8(2):158. doi: 10.3390/healthcare8020158. PMID: 32512888; PMCID: PMC7349344.
2. Mark Emberton, Guiseppe Martorana, BPH: Social Impact and Patient's Perspective, European Urology Supplements, 2006; 5(2): 991-996.https://doi.org/10.1016/j.eursup.2006.08.008.
3. Liu, X., Ma, K., Yang, L. *et al.* The relationship between depression and benign prostatic hyperplasia in middle-aged and elderly men in India: a large-scale population study. *BMC Public Health* **23**, 2152 (2023). https://doi.org/10.1186/s12889-023-17027-2
4. Yu-Hua Fan, Alex T.L. Lin, Yi-Hsiu Huang, Kuang-Kuo Chen,Health care-seeking behavior in benign prostatic hyperplasia patients, Urological Science, 2017;28(3):169-173. https://doi.org/10.1016/j.urols.2016.12.003.
5. Bortnick E, Brown C, Simma-Chiang V, Kaplan SA. Modern best practice in the management of benign prostatic hyperplasia in the elderly. Therapeutic Advances in Urology. 2020;12. doi:10.1177/1756287220929486
6. Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 2011 Nov-Dec;82(4-5):184-99. doi: 10.1016/j.diff.2011.04.006. Epub 2011 May 26. PMID: 21620560; PMCID: PMC3179830.
7. Tristan M. Nicholson, William A. Ricke, Androgens and estrogens in benign prostatic hyperplasia: Past, present and future, Differentiation, 2011; 82(4-5): 184-199. https://doi.org/10.1016/j.diff.2011.04.006.
8. Hata J, Harigane Y, Matsuoka K, Akaihata H, Yaginuma K, Meguro S, Hoshi S, Sato Y, Ogawa S, Uemura M, et al. Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia. *International Journal of Molecular Sciences.* 2023; 24(14):11634. https://doi.org/10.3390/ijms241411634
9. Zhou, XZ., Huang, P., Wu, YK. *et al.* Autophagy in benign prostatic hyperplasia: insights and therapeutic potential. *BMC Urol* **24**, 198 (2024). https://doi.org/10.1186/s12894-024-01585-7
10. Naiyila X, Li J, Huang Y, Chen B, Zhu M, Li J, Chen Z, Yang L, Ai J, Wei Q, et al. A Novel Insight into the Immune-Related Interaction of Inflammatory Cytokines in Benign Prostatic Hyperplasia. *Journal of Clinical Medicine.* 2023; 12(5):1821. https://doi.org/10.3390/jcm12051821
11. Guo, J., Huang, X., Dou, L. *et al.* Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. *Sig Transduct Target Ther* **7**, 391(2022). https://doi.org/10.1038/s41392-022-01251-0
12. Kwon OJ, Zhang L, Ittmann MM, Xin L. Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):E592-600.doi: 10.1073/pnas.1318157111. Epub 2013 Dec 23. PMID: 24367088; PMCID: PMC3918789.
13. Robert I. Uroko., Charles N. Chukwu., Simeon I. Egba1., Fatima A. Adamude andJoy C. Ajuzie. Combined ethanol extract of *Funtumia africana* and *Abutilon*

mauritianium leaves improves the lipid profile and kidney function indices of benign prostatic hyperplasia in rats. *Acta Sci. Pol. Technol. Aliment.* 2020; 19(4): 395-4045

14. Maria Eduarda Almeida Tavares, Allice Santos Cruz Veras, Hayley Hope Allyssa Thorpe, Danilo Bianchini Baptista, Giovana Rampazzo Teixeira, Physical exercise regulates apoptosis and prostatic inflammatory effects induced by high-fat diet in PPAR-alpha deleted mice, Prostaglandins & Other Lipid Mediators, 2022; 163, 106669. https://doi.org/10.1016/j.prostaglandins.2022.106669.
15. Archer M, Dogra N, Kyprianou N. Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance. *Cancers.* 2020; 12(10):2984. https://doi.org/10.3390/cancers12102984
16. Manisha Nigam, Abhay Prakash Mishra, Vishal Kumar Deb, Deen Bandhu Dimri, Vinod Tiwari, Simona Gabriela Bungau, Alexa Florina Bungau, Andrei-Flavius Radu, Evaluation of the association of chronic inflammation and cancer: Insights and implications, Biomedicine & Pharmacotherapy, 2023; 164, 115015. https://doi.org/10.1016/j.biopha.2023.115015.
17. Oseni SO, Naar C, Pavlović M, Asghar W, Hartmann JX, Fields GB, Esiobu N, Kumi-Diaka J. The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer. *Cancers.* 2023; 15(12):3110. https://doi.org/10.3390/cancers15123110
18. Zhao, H., Wu, L., Yan, G. *et al.* Inflammation and tumor progression: signaling pathways and targeted intervention. *Sig Transduct Target Ther* **6**, 263(2021). https://doi.org/10.1038/s41392-021-00658-5
19. Di Maggio, F.M., Minafra, L., Forte, G.I. *et al.* Portrait of inflammatory response to ionizing radiation treatment. *J Inflamm* **12**, 14(2015). https://doi.org/10.1186/s12950-015-0058-3
20. Vicari E, Arancio A, Catania VE, Vicari BO, Sidoti G, Castiglione R, Malaguarnera M. Resveratrol reduces inflammation-related Prostate Fibrosis. *Int J Med Sci* 2020; 17(13):1864-1870. doi:10.7150/ijms.44443. https://www.medsci.org/v17p1864.htm
21. Guo, Q., Jin, Y., Chen, X. *et al.* NF-κB in biology and targeted therapy: new insights and translational implications. *Sig Transduct Target Ther* **9**, 53 (2024). https://doi.org/10.1038/s41392-024-01757-9
22. IR Uroko, F A Adamude, S I Egba, C N Chukwu, C L Asadu, E C Okwara. Effects of combined ethanol extract of *Funtumia africana* and *Abutilon mauritianum* leaves (FAAM) on liver function indices of benign prostatic hyperplasia (BPH) induced rats, *Herba Polonica,2020;* 66 (3): 24-35
23. Amin Ullah, Yongxiu Chen, Rajeev K. Singla, Dan Cao, Bairong Shen, Pro-inflammatory cytokines and CXC chemokines as game-changer in age-associated prostate cancer and ovarian cancer: Insights from preclinical and clinical studies' outcomes, Pharmacological Research, 2024; 204, 107213. https://doi.org/10.1016/j.phrs.2024.107213.
24. Ullah, A., Jiao, W. & Shen, B. The role of proinflammatory cytokines and CXC chemokines (CXCL1–CXCL16) in the progression of prostate cancer: insights on their therapeutic management. *Cell Mol Biol Lett* **29**, 73 (2024). https://doi.org/10.1186/s11658-024-00591-9
25. Amin MN, Siddiqui SA, Ibrahim M, et al. Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer. SAGE Open Medicine. 2020;8. doi:10.1177/2050312120965752
26. Rodriguez-Nieves JA, Macoska JA. Prostatic fibrosis, lower urinary tract symptoms, and BPH. Nat Rev Urol. 2013 Sep;10(9):546-50.doi: 10.1038/nrurol.2013.149. Epub 2013 Jul 16. PMID: 23857178; PMCID: PMC5625295.
27. Uroko Robert Ikechukwu, Fatima Amin Adamude, Egba Simeon Ikechukwu, Chinedu Paulinus Nwuke, Chidinma Lilian Asadu and Peter Anyaorah. Effect of combined ethanol extract of Funtumia Africana and Abutilon mauritanium leaves on prostate biomarkers and serum mineral

levels in prostatic hyperplasia induced in rats. J. Renal Endocrinol 2021; 7:e06

28. Rahardjo HE, Märker V, Tsikas D, Kuczyk MA, Ückert S, Bannowsky A. Fibrotic Diseases of the Human Urinary and Genital Tract: Current Understanding and Potential Strategies for Treatment. *Journal of Clinical Medicine*. 2023; 12(14):4770. https://doi.org/10.3390/jcm12144770
29. Ren, J., Li, Y., Zhang, X. *et al.* Correlation between metabolic syndrome and periurethral prostatic fibrosis: results of a prospective study. *BMC Urol* **24**, 38 (2024). https://doi.org/10.1186/s12894-024-01413-y
30. Martinez-Vidal, L., Murdica, V., Venegoni, C. *et al.* Causal contributors to tissue stiffness and clinical relevance in urology. *Commun Biol* **4**, 1011 (2021). https://doi.org/10.1038/s42003-021-02539-7
31. Kwon JK, Kim DK, Lee JY, Kim JW, Cho KS. Relationship between Lower Urinary Tract Symptoms and Prostatic Urethral Stiffness Using Strain Elastography: Initial Experiences. *Journal of Clinical Medicine*. 2019;8(11):1929. https://doi.org/10.3390/jcm8111929
32. Omer A. Raheem, Fady Ghali, Mahadevan R. Rajasekaran, Chapter 26 - Penile Fibrogenesis Affecting Men's Reproductive and Sexual Health: Role of Age and Environmental Factors, Editor(s): Suresh C. Sikka, Wayne J.G. Hellstrom, Bioenvironmental Issues Affecting Men's Reproductive and Sexual Health, Academic Press, 2018, 423-437, https://doi.org/10.1016/B978-0-12-801299-4.00026-8.

CITE AS: Bizimana Rukundo T. (2024). The Role of Inflammation and Immune Dysregulation in the Pathogenesis of BPH. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 9(3)8-13. https://doi.org/10.59298/IDOSRJSR/2024/9.3.813.100